Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis

Fig. 3

Analysis of anti-BCL6 staining (Part 1): MRONJ (BP) vs. OM vs. ORN vs. control. a Visual field from a MRONJ (BP)-specimen. Note the giant multinucleated OC (arrowhead) with cytoplasmic expression of BCL6 and the surrounding mononuclear cells with nuclear BCL6-expression. b Visual field from a control specimen with an unstained OC (arrowhead). The specimens in a and b underwent anti-BCL6 staining under the same conditions. c Visualizes the number of OCs with nuclear BCL6+ expression per ROI for each group. d Illustrates the number of OCs with cytoplasmic BCL6+ expression per ROI for each group. *Marks statistical outliers. For detailed data see Table 2. MRONJ (BP) medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy, OC osteoclasts, OM osteomyelitis, ORN osteoradionecrosis, BCL6, B-cell lymphoma 6, ROI region of interest

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us